The new therapy, ABD-147, uses advanced antibody engineering to deliver actinium-225 to solid tumors expressing DLL3, a protein found in neuroendocrine tumors.
FDA Grants Fast Track Designation to Abdella Therapeutics’ Advanced Small Cell Lung Cancer Treatment
Leave a comment
